Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), since its outbreak in
December 2019, has been capable of continuing the pandemic by mutating itself into …

Multiple variants of SARS-CoV-2 have emerged and are now prevalent at the global level.
Currently designated variants of concern (VOCs) are B. 1.1. 7, B1. 351, P. 1, B. 1.617. 2 …

SARS-CoV-2 is the causative agent of COVID-19. The main viral protease (M pro) is an
attractive target for antivirals. The clinically approved drug nirmatrelvir and the clinical …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected billions and
has killed millions to date. Studies are being carried out to find therapeutic molecules that …

The aim of this study was to evaluate the effect and safety of N‐acetylcysteine (NAC)
inhalation spray in the treatment of patients with coronavirus disease 2019 (COVID‐19). This …

With the global spread of the corona virus disease-2019 pandemic, new spike variants of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continuously emerge due …

Introduction A large number of risk and protective factors have been identified during the
SARS-CoV-2 pandemic which may influence the outcome of COVID-19. Among these …

Echinacea purpurea has been shown to broadly inhibit coronaviruses and SARS-CoV-2 in
vitro. This review discusses the available clinical evidence from randomized, blinded and …

Abstract Background The Bacillus Calmette–Guérin (BCG) vaccine may confer cross‐
protection against viral diseases in adults. This study evaluated BCG vaccine cross …

Abstract The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has inflicted immense damage to countries …